Oncology
-
Randomized Controlled Trial Multicenter Study
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer. Secondary objectives included overall and progression-free survival, duration of response, toxicities, and biomarkers. ⋯ Neither efficacy nor safety improved on the ALIRI arm compared to the FOLFIRI arm. Progression-free survival on FOLFIRI was significantly longer compared to ALIRI. Potential biomarkers capable of predicting response to either regimen in advanced or metastatic colorectal carcinoma need further characterization.
-
Multicenter Study
Chemotherapy use and associated factors among cancer patients near the end of life.
We investigated the frequency of chemotherapy use and its associated factors in patients in all age groups in the last year of life. ⋯ Despite the fact that most cancer patients are resistant to chemotherapy at the end of life, it was administered often to all age groups.